Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Haematologica

Retrieve available abstracts of 127 articles:
HTML format

Single Articles

    March 2023
  1. WALCZAK P, Choquet S, Dantal J, Boutboul D, et al
    Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.
    Haematologica. 2023 Mar 9. doi: 10.3324/haematol.2022.282297.
    PubMed     Abstract available

  2. ISAKSEN KT, Galleberg R, Mastroianni MA, Rinde M, et al
    The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy.
    Haematologica. 2023 Mar 2. doi: 10.3324/haematol.2022.282289.
    PubMed     Abstract available

  3. WAYNE AS, Huynh V, Hijiya N, Rouce RH, et al
    Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Haematologica. 2023;108:747-760.
    PubMed     Abstract available

  4. BOMKEN S, Enshaei A, Schwalbe EC, Mikulasova A, et al
    Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
    Haematologica. 2023;108:717-731.
    PubMed     Abstract available

    February 2023
  5. BARRACLOUGH A, England JT, Villa D, Wight J, et al
    Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.
    Haematologica. 2023 Feb 23. doi: 10.3324/haematol.2022.281375.
    PubMed     Abstract available

  6. BEWARDER M, Kaddu-Mulindwa D, Kos IA, Lesan V, et al
    Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP.
    Haematologica. 2023 Feb 23. doi: 10.3324/haematol.2022.282126.
    PubMed     Abstract available

  7. KAMEDA T, Kataoka K, Kamiunten A, Hidaka M, et al
    Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.
    Haematologica. 2023 Feb 16. doi: 10.3324/haematol.2022.281510.
    PubMed     Abstract available

  8. CHEN G, Herr M, Nowak J, Ho C, et al
    Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant.
    Haematologica. 2023;108:615-620.

  9. LOPEZ C, Schleussner N, Bernhart SH, Kleinheinz K, et al
    Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas.
    Haematologica. 2023;108:543-554.
    PubMed     Abstract available

    January 2023
  10. DING K, Liu H, Ma J, Yang H, et al
    Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial.
    Haematologica. 2023 Jan 26. doi: 10.3324/haematol.2022.282266.
    PubMed     Abstract available

  11. DI M, Long JB, Kothari SK, Sethi T, et al
    Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.
    Haematologica. 2023 Jan 19. doi: 10.3324/haematol.2022.282252.
    PubMed     Abstract available

  12. SONG JY, Nwangwu M, He TF, Zhang W, et al
    Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma.
    Haematologica. 2023 Jan 12. doi: 10.3324/haematol.2022.282265.
    PubMed     Abstract available

    December 2022
  13. LURAIN K, Ramaswami R, Marshall V, Castro EMC, et al
    Kaposi sarcoma herpesvirus viral load as a biomarker for leptomeningeal involvement by primary effusion lymphoma.
    Haematologica. 2022 Dec 22. doi: 10.3324/haematol.2022.281472.
    PubMed     Abstract available

  14. CHOHAN KL, Young JR, Lester S, Moustafa MA, et al
    End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim-PET.
    Haematologica. 2022 Dec 22. doi: 10.3324/haematol.2022.282115.
    PubMed     Abstract available

  15. PIROSA MC, Sassone M, Kiesewetter B, Guillermo AL, et al
    IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.
    Haematologica. 2022 Dec 22. doi: 10.3324/haematol.2022.281963.
    PubMed     Abstract available

  16. KNORR F, Schellekens KPJ, Schoot RA, Landman-Parker J, et al
    Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma.
    Haematologica. 2022 Dec 15. doi: 10.3324/haematol.2022.281896.
    PubMed     Abstract available

  17. GERDTSSON AS, Matos Rodrigues J, Eskelund CW, Husby S, et al
    Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors.
    Haematologica. 2022 Dec 15. doi: 10.3324/haematol.2022.281420.
    PubMed     Abstract available

  18. LIU Y, Yan F, Jiang VC, Li Y, et al
    Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma.
    Haematologica. 2022 Dec 7. doi: 10.3324/haematol.2022.282031.
    PubMed     Abstract available

  19. DLOUHY I, Armengol M, Recasens-Zorzo C, Ribeiro ML, et al
    Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-kappaB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutati
    Haematologica. 2022;107:2990.

    Images from the Haematologica Atlas of Hematologic Cytology: anaplastic large cell lymphoma, ALK-negative.
    Haematologica. 2022;107:2771.

  21. SULEMAN A, Liu J, Hicks LK, Drori AK, et al
    Methotrexate cytarabine thiotepa rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
    Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.282014.
    PubMed     Abstract available

    Targetting glutaminase to starve lymphoma cells.
    Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.282348.
    PubMed     Abstract available

  23. GOYAL G, Magnusson T, Wang X, Roose J, et al
    Modern real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large-B cell lymphoma with or without double/triple-hit status in the United States.
    Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.281461.

  24. SIBON D, Bisig B, Bonnet C, Poullot E, et al
    ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.
    Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.281442.
    PubMed     Abstract available

  25. QIU L, Tang G, Li S, Vega F, et al
    DUSP22 rearrangement is associated with distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma.
    Haematologica. 2022 Dec 1. doi: 10.3324/haematol.2022.281222.
    PubMed     Abstract available

    November 2022
  26. HIRAMATSU H, Nosaka K, Kusumoto S, Nakano N, et al
    Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma.
    Haematologica. 2022 Nov 24. doi: 10.3324/haematol.2022.281435.
    PubMed     Abstract available

  27. LI L, Nie L, Jordan A, Cai Q, et al
    Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma.
    Haematologica. 2022 Nov 24. doi: 10.3324/haematol.2022.281538.
    PubMed     Abstract available

  28. JALLOUK AP, Gouni S, Westin J, Feng L, et al
    Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
    Haematologica. 2022 Nov 17. doi: 10.3324/haematol.2022.281954.
    PubMed     Abstract available

  29. LIU Y, Derkach A, Lewis N, Zhu M, et al
    Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm.
    Haematologica. 2022 Nov 17. doi: 10.3324/haematol.2022.281724.
    PubMed     Abstract available

  30. TUCCI A, Merli F, Fabbri A, Marcheselli L, et al
    Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL).
    Haematologica. 2022 Nov 17. doi: 10.3324/haematol.2022.281407.
    PubMed     Abstract available

  31. BOBILLO S, Khwaja J, Ferreri AJ, Cwynarski K, et al
    Prevention and management of secondary central nervous system lymphoma.
    Haematologica. 2022 Nov 17. doi: 10.3324/haematol.2022.281457.
    PubMed     Abstract available

  32. QIU L, Xu J, Lin P, Cohen EN, et al
    Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B acute lymphoblastic leukemia/lymphoma.
    Haematologica. 2022 Nov 3. doi: 10.3324/haematol.2022.281646.
    PubMed     Abstract available

  33. FORGEARD N, Baron M, Caron J, Boccon-Gibod C, et al
    Inflammation in Waldenstrom macroglobulinemia is associated with 6q deletion and need for treatment initiation.
    Haematologica. 2022;107:2720-2724.

  34. BACHY E
    Mature T-cell neoplasms and stem cell transplant: the never-ending story.
    Haematologica. 2022;107:2534-2535.

    October 2022
  35. KHWAJA J, Kirkwood AA, Isbell LK, Steffanoni S, et al
    International multicentre retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.
    Haematologica. 2022 Oct 27. doi: 10.3324/haematol.2022.281640.
    PubMed     Abstract available

  36. DOGAN A
    The real risk of secondary non-Hodgkin lymphoma following Classical Hodgkin lymphoma.
    Haematologica. 2022 Oct 20. doi: 10.3324/haematol.2022.281700.
    PubMed     Abstract available

  37. GHIONE P, Palomba ML, Ghesquieres H, Bobillo S, et al
    Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
    Haematologica. 2022 Oct 20. doi: 10.3324/haematol.2022.281421.
    PubMed     Abstract available

  38. BOOT MV, Schaapveld M, Van den Broek EC, Hijmering NJ, et al
    Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nation-wide cohort: Implications for clinical and epidemiological studies Authors.
    Haematologica. 2022 Oct 20. doi: 10.3324/haematol.2022.280840.
    PubMed     Abstract available

  39. THUS YJ, De Rooij MFM, Swier N, Beijersbergen RL, et al
    Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
    Haematologica. 2022 Oct 13. doi: 10.3324/haematol.2022.281668.
    PubMed     Abstract available

  40. RAI S, Kim WS, Ando K, Choi I, et al
    Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
    Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.280996.
    PubMed     Abstract available

    September 2022
  41. DEMEL UM, Wirth M, Yousefian S, Zhang L, et al
    Small molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.
    Haematologica. 2022 Sep 22. doi: 10.3324/haematol.2022.280995.
    PubMed     Abstract available

  42. KHWAJA J, D'Sa S, Minnema MC, Kersten MJ, et al
    IgM monoclonal gammopathies of clinical significance: diagnosis and management.
    Haematologica. 2022;107:2037-2050.
    PubMed     Abstract available

  43. CABANNES-HAMY A, Brissot E, Leguay T, Huguet F, et al
    High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.
    Haematologica. 2022;107:2072-2080.
    PubMed     Abstract available

  44. WANG X, Su W, Gao Y, Feng Y, et al
    A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.
    Haematologica. 2022;107:2154-2162.
    PubMed     Abstract available

    August 2022
  45. FISHER KE, Ferguson LS, Coffey AM, Merritt BY, et al
    Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.
    Haematologica. 2022;107:1880-1890.
    PubMed     Abstract available

    July 2022
  46. FALINI L, Venanzi A, Tini V, Innocente A, et al
    Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis.
    Haematologica. 2022 Jul 28. doi: 10.3324/haematol.2022.281351.
    PubMed     Abstract available

  47. ZURKO J, Ramdial J, Shadman M, Ahmed S, et al
    Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
    Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.281242.
    PubMed     Abstract available

  48. GANDHI MK, Keane C
    CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma.
    Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.281440.
    PubMed     Abstract available

  49. STEPHENS DM, Li H, Constine LS, Fitzgerald TJ, et al
    Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.
    Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.281004.
    PubMed     Abstract available

  50. TAYLOR JG, Truelove E, Clear A, Calaminici M, et al
    PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion.
    Haematologica. 2022 Jul 14. doi: 10.3324/haematol.2022.280014.
    PubMed     Abstract available

    Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
    Haematologica. 2022;107:1500-1502.

  52. MAJOR A, Kline J, Karrison TG, Fishkin PAS, et al
    Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
    Haematologica. 2022;107:1608-1618.
    PubMed     Abstract available

    June 2022
  53. KWON M, Iacoboni G, Reguera JL, Corral LL, et al
    Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
    Haematologica. 2022 Jun 30. doi: 10.3324/haematol.2022.280805.
    PubMed     Abstract available

  54. FUJI S, Yasunaga JI, Watanabe E, Matsuoka M, et al
    Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation.
    Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.281175.
    PubMed     Abstract available

  55. ISAEV K, Liu T, Bakhtiari M, Tong K, et al
    In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.
    Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.280900.
    PubMed     Abstract available

  56. VELOZA L, Cavalieri D, Missiaglia E, Ledoux-Pilon A, et al
    Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.
    Haematologica. 2022 Jun 16. doi: 10.3324/haematol.2022.281226.
    PubMed     Abstract available

  57. GALTIER J, Vercellino L, Chartier L, Olivier P, et al
    PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells.
    Haematologica. 2022 Jun 9. doi: 10.3324/haematol.2021.280550.
    PubMed     Abstract available

    May 2022
  58. ROSSI C, Andre M, Dupuis J, Morschhauser F, et al
    High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.
    Haematologica. 2022 May 31. doi: 10.3324/haematol.2021.280004.
    PubMed     Abstract available

  59. MADUGULA KK, Joseph J, DeMarino C, Ginwala R, et al
    Regulation of Human T-cell Leukemia Virus type 1 antisense promoter by Myocyte Enhancer Factor-2C in the context of Adult T-cell leukemia and lymphoma.
    Haematologica. 2022 May 26. doi: 10.3324/haematol.2021.279542.
    PubMed     Abstract available

  60. SARKOZY C, Salles G
    PET-CT before autologous stem cell transplant in follicular lymphoma: coming too late?
    Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.281255.
    PubMed     Abstract available

  61. EYRE TA, Barrington SF, Okosun J, Abamba C, et al
    Impact of PET-CT status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplant.
    Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.280287.
    PubMed     Abstract available

  62. RIGAUD C, Abbou S, Ducassou S, Simonin M, et al
    Profound and sustained response with next generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement.
    Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.280081.
    PubMed     Abstract available

  63. PICOD A, Martino S, Cervera P, Manuceau G, et al
    Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T cell lymphoma.
    Haematologica. 2022 May 5. doi: 10.3324/haematol.2021.280349.
    PubMed     Abstract available

  64. MEI M, Hamadani M, Ahn KW, Chen Y, et al
    Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit.
    Haematologica. 2022;107:1214-1217.

  65. ESCHERICH G, Zur Stadt U, Borkhardt A, Dilloo D, et al
    Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative
    Haematologica. 2022;107:1026-1033.
    PubMed     Abstract available

  66. GAO J, Wang MY, Ren Y, Lwin T, et al
    Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
    Haematologica. 2022;107:1119-1130.
    PubMed     Abstract available

    April 2022
  67. SMELAND K, Holte H, Fagerli UM, Bersvendsen H, et al
    Total late effect burden in long-term lymphoma survivors after highdose therapy with autologous stem-cell transplant and its effect on health-related quality of life.
    Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.280413.
    PubMed     Abstract available

  68. ARRIBAS AJ, Napoli S, Cascione L, Sartori G, et al
    Resistance to PI3kappadelta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
    Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.279957.
    PubMed     Abstract available

  69. CLOSE K, Fitzgibbon J
    KDM4C in GC lymphoma: a new piece of the epigenetic puzzle.
    Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2022.280898.
    PubMed     Abstract available

  70. TANAKA N, Mori S, Kiyotani K, Ota Y, et al
    Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
    Haematologica. 2022 Apr 14. doi: 10.3324/haematol.2021.280352.
    PubMed     Abstract available

    Images from the Haematologica Atlas of Hematologic Cytology: precursor lymphoid neoplasms, cytochemistry and immunocytochemistry.
    Haematologica. 2022;107:781.

  72. CORREIA E, Cha J, Krishnasamy S, O'Donnell M, et al
    A case series of primary cutaneous B-cell lymphomas with atypical presentations: diagnostic and therapeutic challenges.
    Haematologica. 2022;107:1014-1016.

  73. TANAGER KS, Yu J, Chiu BC, Carll TC, et al
    Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators.
    Haematologica. 2022;107:966-969.

  74. VISENTIN A, Bonaldi L, Rigolin GM, Mauro FR, et al
    The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.
    Haematologica. 2022;107:868-876.
    PubMed     Abstract available

    March 2022
  75. KIM M, Hwang HS, Yoon DH, Chun SM, et al
    Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma.
    Haematologica. 2022 Mar 31. doi: 10.3324/haematol.2021.280543.
    PubMed     Abstract available

  76. QUIVORON C, Tarabay A, Michot JM, Pages A, et al
    Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B cell lymphoma.
    Haematologica. 2022 Mar 24. doi: 10.3324/haematol.2021.280464.
    PubMed     Abstract available

  77. GARCIA-SANCHO AM, Bellei M, Lopez-Parra M, Gritti G, et al
    Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
    Haematologica. 2022 Mar 24. doi: 10.3324/haematol.2021.279426.
    PubMed     Abstract available

    A BAFFling menage a trois in mantle cell lymphoma.
    Haematologica. 2022 Mar 10. doi: 10.3324/haematol.2022.280721.
    PubMed     Abstract available

  79. DECOMBIS S, Papin A, Bellanger C, Sortais C, et al
    The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.
    Haematologica. 2022 Mar 10. doi: 10.3324/haematol.2021.279800.
    PubMed     Abstract available

  80. DOURTHE ME, Phulpin A, Auperin A, Bosq J, et al
    Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
    Haematologica. 2022 Mar 3. doi: 10.3324/haematol.2021.280257.
    PubMed     Abstract available

  81. CANDON S, Lemee V, Leveque E, Etancelin P, et al
    Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas.
    Haematologica. 2022;107:755-758.

    February 2022
  82. BOUARD L, Tessoulin B, Thieblemont C, Bouabdallah K, et al
    Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma.
    Haematologica. 2022 Feb 17. doi: 10.3324/haematol.2021.279561.
    PubMed     Abstract available

  83. KORONA B, Korona D, Zhao W, Wotherspoon AC, et al
    CCR6 activation links innate immune responses to MALT lymphoma development.
    Haematologica. 2022 Feb 10. doi: 10.3324/haematol.2021.280067.
    PubMed     Abstract available

  84. CASHEN AF, Bartlett NL
    Stem cell transplant for lymphoma - never too late?
    Haematologica. 2022 Feb 3. doi: 10.3324/haematol.2021.280519.
    PubMed     Abstract available

  85. SMITH S
    Too much and not enough: revisiting maintenance rituximab in indolent lymphomas.
    Haematologica. 2022;107:353-354.

    January 2022
  86. WAI CMM, Chen S, Phyu T, Fan S, et al
    Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.
    Haematologica. 2022 Jan 13. doi: 10.3324/haematol.2021.280003.
    PubMed     Abstract available

  87. KOCH K, Richter J, Hanel C, Huttmann A, et al
    Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/transformation.
    Haematologica. 2022 Jan 13. doi: 10.3324/haematol.2021.279351.
    PubMed     Abstract available

  88. CHEAH CY, Zucca E, Rossi D, Habermann TM, et al
    Marginal zone lymphoma: present status and future perspectives.
    Haematologica. 2022;107:35-43.

  89. QUALLS D, Salles G
    Prospects in the management of patients with follicular lymphoma beyond first-line therapy.
    Haematologica. 2022;107:19-34.
    PubMed     Abstract available

  90. CARTRON G, Trotman J
    Time for an individualized approach to first-line management of follicular lymphoma.
    Haematologica. 2022;107:7-18.
    PubMed     Abstract available

  91. SMITH SM, Salles G
    Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges.
    Haematologica. 2022;107:4-6.

    Images from the Haematologica Atlas of Hematologic Cytology: Sezary syndrome.
    Haematologica. 2022;107:1.

    December 2021
  93. MAROUF A, Cottereau AS, Kanoun S, Deschamps P, et al
    Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study.
    Haematologica. 2021 Dec 30. doi: 10.3324/haematol.2021.279564.
    PubMed     Abstract available

  94. KIM HT, Baker PO, Parry E, Davids M, et al
    Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.
    Haematologica. 2021;106:3219-3222.

    November 2021
  95. KOHN M, Delord M, Chbat M, Guemriche A, et al
    A third anti-SARS-Cov2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
    Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.280026.
    PubMed     Abstract available

  96. KUNSTNER A, Witte HM, Riedl J, Bernard V, et al
    Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing.
    Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.279631.
    PubMed     Abstract available

  97. ALBERTSSON-LINDBLAD A, Palsdottir T, Smedby KE, Weibull CE, et al
    Survival in mantle cell lymphoma after frontline treatment with Rbendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
    Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.279037.
    PubMed     Abstract available

  98. STEINER RE, Banchs J, Koutroumpakis E, Becnel M, et al
    Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma.
    Haematologica. 2021 Nov 11. doi: 10.3324/haematol.2021.280009.
    PubMed     Abstract available

    September 2021
  99. CASAGRANDE N, Borghese C, Aldinucci D
    In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases 3D tumor-stroma heterospheroid viability.
    Haematologica. 2021 Sep 9. doi: 10.3324/haematol.2021.279389.
    PubMed     Abstract available

  100. KNORR F, Zimmermann M, Attarbaschi A, Kabickova E, et al
    Dose-adjusted EPOCH-Rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
    Haematologica. 2021 Sep 9. doi: 10.3324/haematol.2021.278971.
    PubMed     Abstract available

    Preventing central nervous system spread in diffuse large B-cell lymphoma - novel approaches needed.
    Haematologica. 2021;106:2298-2300.

  102. DONG G, Li Y, Lee L, Liu X, et al
    Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.
    Haematologica. 2021;106:2427-2438.
    PubMed     Abstract available

    August 2021
  103. DUELL J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al
    Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Haematologica. 2021 Aug 19. doi: 10.3324/haematol.2021.279802.
    PubMed     Abstract available

  104. KOSTAKOGLU L, Mattiello F, Martelli M, Sehn LH, et al
    Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
    Haematologica. 2021 Aug 19. doi: 10.3324/haematol.2021.278663.
    PubMed     Abstract available

  105. BASTIDAS TORRES AN, Melchers RC, Van Grieken L, Out-Luiting JJ, et al
    Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.
    Haematologica. 2021 Aug 12. doi: 10.3324/haematol.263251.
    PubMed     Abstract available

  106. KIM M, Lee JO, Koh J, Kim TM, et al
    A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.
    Haematologica. 2021;106:2277-2280.

    July 2021
  107. GURION R, Rozovski U, Itchaki G, Gafter-Gvili A, et al
    Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
    Haematologica. 2021 Jul 29. doi: 10.3324/haematol.2021.279216.
    PubMed     Abstract available

  108. LIN RJ, Owens CN, Drill E, Iannotta A, et al
    Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
    Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.278719.
    PubMed     Abstract available

  109. DODERO A, Guidetti A, Marino F, Tucci A, et al
    Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
    Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.278638.
    PubMed     Abstract available

  110. STRATI P, De Vos S, Ruan J, Maddocks KJ, et al
    Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study.
    Haematologica. 2021 Jul 8. doi: 10.3324/haematol.2021.278654.
    PubMed     Abstract available

  111. RAM R, Grisariu S, Shargian-Alon L, Amit O, et al
    Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients - a matched control multi-center cohort study.
    Haematologica. 2021 Jul 8. doi: 10.3324/haematol.2021.278288.
    PubMed     Abstract available

  112. DUELL J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al
    Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Haematologica. 2021 Jul 1. doi: 10.3324/haematol.2020.275958.
    PubMed     Abstract available

    June 2021
  113. BENKLI CY, Marcogliese AN, Agrusa JE, Adesina AM, et al
    Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2021.278936.
    PubMed     Abstract available

  114. EVENS AM, Connors JM, Younes A, Ansell SM, et al
    Older patients (aged >/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2021.278438.
    PubMed     Abstract available

  115. NAPOLI S, Cascione L, Rinaldi A, Spriano F, et al
    Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2020.267096.
    PubMed     Abstract available

  116. RULE S, Barreto WG, Briones J, Carella AM, et al
    Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study.
    Haematologica. 2021 Jun 17. doi: 10.3324/haematol.2020.274803.
    PubMed     Abstract available

  117. PECE R, Tavella S, Costa D, Varesano S, et al
    Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
    Haematologica. 2021 Jun 10. doi: 10.3324/haematol.2021.278469.
    PubMed     Abstract available

  118. SVOBODA J, Bair SM, Landsburg DJ, Dwivedy Nasta S, et al
    Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
    Haematologica. 2021;106:1705-1713.
    PubMed     Abstract available

    May 2021
  119. DLOUHY I, Armengol M, Recasens-Zorzo C, Ribeiro ML, et al
    Interleukin-1 receptor associated kinase 1/4 and bromodomain and extraterminal inhibitions converge on NF-kappaB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88(L265P) mutati
    Haematologica. 2021 May 13. doi: 10.3324/haematol.2020.278258.
    PubMed     Abstract available

  120. PILERI SA, Mazzara S, Derenzini E
    Plasmablastic lymphoma: one or more tumours?
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2021.278841.

  121. NIETO Y, Gruschkus S, Valdez BC, Jones RB, et al
    Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2021.278311.
    PubMed     Abstract available

  122. RAMIS-ZALDIVAR JE, Gonzalez-Farre B, Nicolae A, Pack S, et al
    MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2020.271957.
    PubMed     Abstract available

    April 2021
  123. STRAUS DJ
    Progress in understanding the biology of nodular lymphocyte predominant Hodgkin lymphoma.
    Haematologica. 2021 Apr 22. doi: 10.3324/haematol.2021.278785.
    PubMed     Abstract available

  124. PASCHOLD L, Willscher E, Bein J, Vornanen M, et al
    Evolutionary clonal trajectories in nodular lymphocyte predominant Hodgkin lymphoma with high transformation risk.
    Haematologica. 2021 Apr 22. doi: 10.3324/haematol.2021.278427.
    PubMed     Abstract available

    February 2021
  125. BOBILLO S, Crespo M, Escudero L, Mayor R, et al
    Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
    Haematologica. 2021;106:513-521.
    PubMed     Abstract available

    March 2020
  126. WANG Y, Tschautscher MA, Rabe KG, Call TG, et al
    Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.
    Haematologica. 2020;105:765-773.
    PubMed     Abstract available

    January 2020
  127. STRATI P, Nastoupil LJ, Davis RE, Fayad LE, et al
    A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.
    Haematologica. 2020;105:e26-e28.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.